Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate
Executive Summary
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.
You may also be interested in...
How The Curtain Finally Closed On Ferring/Blackstone’s Gene Therapy Venture FerGene
Having failed to live up to its promising beginnings, FerGene, the gene therapy firm founded with the backing of Ferring and Blackstone to advance the former’s candidate for bladder cancer is back under the Swiss pharma's wing. However, doubts about its future and that of nadofaragene firadonavec remain.
Sanofi Vaccines Chief Loew To Be Ipsen CEO
Sanofi Pasteur head David Loew has been at the heart of the company's bids to develop vaccines for COVID-19 but has decided to accept a different challenge instead and take the helm at Ipsen.
Blow To Ipsen As FerGene Nabs CEO Meek
The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.